ML355 Modulates Platelet Activation and Prevents ABT-737 Induced Apoptosis in Platelets
Open Access
- 1 May 2022
- journal article
- research article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 381 (2) , 164-175
Abstract
12-lipoxigenase (12-LOX) is implicated in regulation of platelet activation processes and can be a new promising target for antiplatelet therapy. However, investigations of 12-LOX were restricted by the lack of specific and potent 12-LOX inhibitors and by controversial data concerning the role of 12-LOX metabolites in platelet functions. A novel specific 12-LOX inhibitor ML355 was shown to inhibit platelet aggregation without adverse side effects on hemostasis; however, the molecular mechanisms of its action on platelets are poorly understood. Here, we showed that ML355 inhibited platelet activation induced by thrombin or thromboxane A2, but not by collagen-related peptide. ML355 blocked protein kinase B, phosphoinositide 3-kinase, and extracellular signal-regulated kinase, but not p38 kinase, spleen tyrosine kinase (Syk), or phospholipase Cγ2 phosphorylation in activated platelets. The main inhibitory effect of low doses of ML355 (1–20 μM) on thrombin activated platelets was mediated by the decrease in reactive oxygen species level, whereas high doses of ML355 (50 μM) caused cyclic adenosine monophosphate activation. ML355 did not affect the activity of nitric oxide-dependent soluble guanylyl cyclase, nor did it affect the relaxation of preconstricted aortic rings in mice. ML355 itself did not affect platelet viability, but at 50 μM dose blocked caspase-dependent apoptosis induced by B-cell lymphoma II inhibitor ABT-737. SIGNIFICANCE STATEMENT The current paper provides novel and original data concerning molecular mechanisms of 12-LOX inhibitor ML355 action on platelets. These data reveal antiplatelet and protective effects of ML355 on platelets and may be of importance for both antiplatelet and anticancer therapy.Keywords
This publication has 77 references indexed in Scilit:
- 12-lipoxygenase activity plays an important role in PAR4 and GPVI-mediated platelet reactivityThrombosis and Haemostasis, 2013
- The first comprehensive and quantitative analysis of human platelet protein composition allows the comparative analysis of structural and functional pathwaysBlood, 2012
- The G-protein regulator LGN modulates the activity of the NO receptor soluble guanylate cyclaseBiochemical Journal, 2012
- Identification of the Orphan G Protein-coupled Receptor GPR31 as a Receptor for 12-(S)-Hydroxyeicosatetraenoic AcidJournal of Biological Chemistry, 2011
- Bioactive Lipoxygenase Metabolites Stimulation of NADPH Oxidases and Reactive Oxygen SpeciesMolecules and Cells, 2011
- GPVI and CLEC‐2 in hemostasis and vascular integrityJournal of Thrombosis and Haemostasis, 2010
- Thrombin and Collagen Induce a Feedback Inhibitory Signaling Pathway in Platelets Involving Dissociation of the Catalytic Subunit of Protein Kinase A from an NFκB-IκB ComplexJournal of Biological Chemistry, 2010
- Thrombin stimulation of p38 MAP kinase in human platelets is mediated by ADP and thromboxane A2 and inhibited by cGMP/cGMP-dependent protein kinaseBlood, 2006
- Nordihydroguaiaretic acid is a potentin vitroscavenger of peroxynitrite, singlet oxygen, hydroxyl radical, superoxide anion and hypochlorous acid and preventsin vivoozone-induced tyrosine nitration in lungsFree Radical Research, 2006
- Hydroxyeicosanoids Bind to and Activate the Low Affinity Leukotriene B4 Receptor, BLT2Journal of Biological Chemistry, 2001